PHILADELPHIA--(BUSINESS WIRE)--Vivodyne, a biotech that discovers and develops more effective drugs by testing them on lab-grown human organs, today announced the close of $38 million in total seed ...

Vivodyne has launched with $38 million in seed funding, led by the investment firm Khosla Ventures, to discover and develop drugs by testing them on lab-grown human organs. The Philadelphia-based ...

Khosla Ventures-backed Vivodyne is growing human tissues in the lab to test potential new therapies before they go to clinical trials. Only about 10% of drugs in development ever make it to market.